Reviewing the Recommendations for Lupus in Children

Arici Z. S., Batu E. D., ÖZEN S.

CURRENT RHEUMATOLOGY REPORTS, cilt.17, sa.3, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 3
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s11926-014-0489-5
  • Dergi Adı: CURRENT RHEUMATOLOGY REPORTS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Systemic lupus erythematosus, SLE, Child, Pediatric, Management, Lupus nephritis, STAGE RENAL-DISEASE, ANTIPHOSPHOLIPID ANTIBODY SYNDROME, MYCOPHENOLATE-MOFETIL TREATMENT, MACROPHAGE ACTIVATION SYNDROME, AUTOIMMUNE HEMOLYTIC-ANEMIA, INTRAVENOUS IMMUNE GLOBULIN, CONTROLLED CLINICAL-TRIAL, COLONY-STIMULATING FACTOR, LONG-TERM MANAGEMENT, DOUBLE-BLIND
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disorder with severe morbidity and mortality and diverse systemic involvement. Disease onset occurs during childhood in approximately 15 % of patients with SLE. It is important to treat the attacks adequately and prevent further flares for favorable long-term outcomes. The aim of effective disease management with early immunosuppression is to achieve symptomatic resolution and improvement in the quality of life by maintaining sustained remission and thereby preventing tissue damage. Adult literature on SLE management has evolved considerably over the past few decades based on observations from clinical studies investigating different immunosuppressive agents. We lack well-designed randomized controlled trials in children with SLE, thus we mainly depend on adult literature. Here, we review the literature for the current management of SLE in children and we present the recommendations and suggestions with the level of evidence.